journal article·2025-01-22

A Supramolecular Deferoxamine–Crisaborole Nanoparticle Targets Ferroptosis, Inflammation, and Oxidative Stress in the Treatment of Retinal Ischemia/Reperfusion Injury

Yiteng Lu, Fang Zhu, Xujiao Zhou, Yuhan Li, Guangyu Rong, Nan Liu, Jiaxu Hong, Yiyun Cheng

Nano Letters· Volume 25· Issue 3
Publisher page

Abstract

Retinal ischemia–reperfusion (IR) injury is a major cause of vision loss worldwide, with ferroptosis, oxidative stress, and inflammation playing key roles in its pathogenesis. Currently, treatments targeting multiple aspects of this condition are limited. This study introduces a supramolecular nanoparticle combining the phosphodiesterase 4 (PDE4) inhibitor crisaborole and the ferroptosis inhibitor deferoxamine to address these pathological processes. Crisaborole forms a dynamic bond with deferoxamine via benzoxaborole–catechol chemistry, creating an amphiphilic molecule that assembles into nanoparticles. Treatment with these nanoparticles enhances glutathione peroxidase 4 (GPX4) levels, downregulates ferroptosis-related genes [Acyl-CoA synthetase long chain family member 4 ( Acsl4 ), heme oxygenase 1 ( Hmox1 )], reduces inflammatory markers (interleukin-1 beta, interleukin-6, tumor necrosis factor alpha), and decreases reactive oxygen species. Electroretinogram and histochemical analysis confirm the nanoparticles’ superior protective effects compared to control treatments. This study proposes a novel nanoparticle approach for retinal IR injury by simultaneously targeting multiple pathogenic pathways.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Adenosine and Purinergic Signaling

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, 200031, China

Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, 200241, China

NHC Key laboratory of Myopia and Related Eye Diseases, Shanghai, 200031, China

Shanghai Engineering Research Center of Synthetic Immunology, Shanghai, 200032, China

Department of Ophthalmology, Children’s Hospital of Fudan University, National Pediatric Medical Center of China, Shanghai, 201102, China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Shanghai Medical Innovation Research Program

References (44)

Show source-provided references
1. 10.1016/j.preteyeres.2003.12.00110.1016/j.preteyeres.2003.12.001 ↗
2. 10.1016/S0140-6736(18)31550-210.1016/S0140-6736(18)31550-2 ↗
3. 10.1186/s12974-022-02621-910.1186/s12974-022-02621-9 ↗
4. 10.3390/ijms2412989210.3390/ijms24129892 ↗
5. 10.1038/s41418-022-01046-410.1038/s41418-022-01046-4 ↗
6. 10.1021/acsnano.3c0053510.1021/acsnano.3c00535 ↗
7. 10.1039/D4NR00611A10.1039/D4NR00611A ↗
8. 10.1016/j.bbi.2019.05.02110.1016/j.bbi.2019.05.021 ↗
9. 10.1016/j.biomaterials.2020.12060010.1016/j.biomaterials.2020.120600 ↗
10. 10.1021/acs.nanolett.4c0093710.1021/acs.nanolett.4c00937 ↗
11. 10.1007/s12274-021-4066-810.1007/s12274-021-4066-8 ↗
12. 10.1016/j.tips.2020.04.00810.1016/j.tips.2020.04.008 ↗
13. 10.1021/ja109665t10.1021/ja109665t ↗
14. 10.1155/2022/491120510.1155/2022/4911205 ↗
15. 10.1021/acscentsci.9b0028410.1021/acscentsci.9b00284 ↗
16. 10.1038/s41392-023-01606-110.1038/s41392-023-01606-1 ↗
17. 10.1016/j.progpolymsci.2024.10185710.1016/j.progpolymsci.2024.101857 ↗
18. 10.31635/ccschem.022.20210169610.31635/ccschem.022.202101696 ↗
19. 10.1038/nbt0614-50510.1038/nbt0614-505 ↗
20. 10.1001/jamadermatol.2019.000810.1001/jamadermatol.2019.0008 ↗
21. 10.1038/s41419-017-0171-810.1038/s41419-017-0171-8 ↗
22. 10.1021/acsmacrolett.8b0043410.1021/acsmacrolett.8b00434 ↗
23. 10.1016/j.jconrel.2023.02.02710.1016/j.jconrel.2023.02.027 ↗
24. 10.1021/acsami.1c0049110.1021/acsami.1c00491 ↗
25. 10.1002/anie.20221300010.1002/anie.202213000 ↗
26. 10.1021/es050275k10.1021/es050275k ↗
27. 10.1021/acs.chemrev.8b0025410.1021/acs.chemrev.8b00254 ↗
28. 10.1002/anie.20130574710.1002/anie.201305747 ↗
29. 10.1021/jacs.3c0803210.1021/jacs.3c08032 ↗
30. 10.1021/jacs.2c0913910.1021/jacs.2c09139 ↗
31. 10.1021/jacs.2c1277210.1021/jacs.2c12772 ↗
32. 10.1016/j.freeradbiomed.2018.09.01410.1016/j.freeradbiomed.2018.09.014 ↗
33. 10.1016/j.freeradbiomed.2022.12.08610.1016/j.freeradbiomed.2022.12.086 ↗
34. 10.1038/s41392-022-00917-z10.1038/s41392-022-00917-z ↗
35. 10.1152/physrev.00003.201610.1152/physrev.00003.2016 ↗
36. 10.1016/j.lfs.2021.11993510.1016/j.lfs.2021.119935 ↗
37. 10.1002/advs.20220679810.1002/advs.202206798 ↗
38. 10.1016/j.redox.2021.10197110.1016/j.redox.2021.101971 ↗
39. 10.3892/or.2021.803910.3892/or.2021.8039 ↗
40. 10.1038/s41419-019-2064-510.1038/s41419-019-2064-5 ↗
41. 10.1016/j.preteyeres.2023.10116910.1016/j.preteyeres.2023.101169 ↗
42. 10.1016/j.nbd.2016.05.00210.1016/j.nbd.2016.05.002 ↗
43. 10.1007/s11427-015-4860-110.1007/s11427-015-4860-1 ↗
44. 10.1186/s12974-019-1424-510.1186/s12974-019-1424-5 ↗